Your browser doesn't support javascript.
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Agrawal, Manasi; Brenner, Erica J; Zhang, Xian; Colombel, Jean-Frederic; Kappelman, Michael D; Ungaro, Ryan C; Gearry, Richard B; Kalpan, Gilaad G; Kissous-Hunt, Michele; Lewis, James D; Ng, Siew C; Rahier, Jean-Francois; Reinisch, Walter; Ruemmele, Frank M; Steinwurz, Flavio; Underwood, Fox E.
  • Agrawal M; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Brenner EJ; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
  • Zhang X; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
  • Colombel JF; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kappelman MD; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
  • Ungaro RC; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Crohns Colitis ; 15(5): 860-863, 2021 May 04.
Article in English | MEDLINE | ID: covidwho-940842
ABSTRACT

BACKGROUND:

We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry.

METHODS:

IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection.

RESULTS:

Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn's disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns.

CONCLUSIONS:

IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Practice Patterns, Physicians&apos; / Inflammatory Bowel Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: J Crohns Colitis Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: Ecco-jcc

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Practice Patterns, Physicians&apos; / Inflammatory Bowel Diseases / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Adult / Female / Humans / Male Language: English Journal: J Crohns Colitis Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: Ecco-jcc